Fermenting wheat with Candida phyllophila J14-4 generated ACE-inhibitory peptides that lowered blood pressure comparably to captopril in hypertensive rats, with the best peptide achieving 93.23% ACE inhibition.
93.23% ACE inhibitionThe most active peptide fraction from fermented wheat achieved 93.23% ACE inhibition in vitro, rivaling pharmaceutical ACE inhibitors
What the researchers found
Fermenting wheat with the yeast Candida phyllophila J14-4 increased angiotensin-converting enzyme (ACE) inhibition activity by 46.05%. Peptide components under 3 kDa in the fermented wheat showed strong ACE-inhibitory activity, with the most potent peptide reaching 93.23% inhibition. In spontaneously hypertensive rats, the antihypertensive effect of the fermented wheat was comparable to captopril, a standard prescription ACE inhibitor drug.
Why it matters
With hypertension affecting over 25% of adults globally, finding food-derived alternatives or complements to pharmaceutical ACE inhibitors is of great interest. This study shows that a simple fermentation process can generate bioactive peptides from wheat that rival a prescription drug's blood pressure-lowering effect in animal models — pointing toward functional foods as a hypertension management tool.
How the study worked
Researchers fermented wheat wort with Candida phyllophila J14-4 and measured ACE inhibition activity in vitro. The antihypertensive effect was tested in vivo using spontaneously hypertensive rats (SHR), with captopril as a positive control. Volatile compounds were characterized using GC-IMS, and peptide fractions were separated by molecular weight to identify the most active ACE-inhibitory components.
Who was studied
Spontaneously hypertensive rats (SHR)
What this study cannot tell us
This is an animal study in spontaneously hypertensive rats, which may not predict blood pressure effects in humans. The fermented wheat product is not standardized for clinical use. The specific peptide sequences responsible for ACE inhibition were not fully identified. Bioavailability of the peptides after oral consumption in humans is unknown.
How to read the evidence
This is a preliminary-grade study combining in vitro enzyme inhibition assays with an animal blood pressure model. While the results are promising, human clinical trials are needed to confirm bioavailability and efficacy of the fermented wheat peptides.
When this study was published
Published in 2025, this is very recent research in the growing field of food-derived bioactive peptides for cardiovascular health.
The bigger picture
Food-derived bioactive peptides are an expanding area of research at the intersection of nutrition and pharmacology. ACE-inhibitory peptides have been found in milk, fish, soy, and now fermented wheat. This study adds a new fermentation approach that could lead to functional foods or nutraceuticals for blood pressure management, potentially reducing dependence on pharmaceutical ACE inhibitors.
Questions still open
- Can these ACE-inhibitory peptides survive human digestion and maintain their blood pressure-lowering activity after oral consumption?
- What are the specific amino acid sequences of the most potent ACE-inhibitory peptides generated by this fermentation process?
- Could fermented wheat products be developed as a practical dietary intervention for mild hypertension in humans?
Common questions
What are ACE-inhibitory peptides and how do they lower blood pressure?
Could fermented wheat replace blood pressure medication?
Read the original research
Boosting health: Candida phyllophila J14-4 fermentation enhances angiotensin-converting enzyme inhibition and antihypertensive properties in wheat wort.
Food chemistry, 495(Pt 3), 146533
Citation
Guo, Xing; Wang, Maomao; Cheng, Yifan; Hu, Zeyu; Yuan, Yahong; Yue, Tianli. (2025). Boosting health: Candida phyllophila J14-4 fermentation enhances angiotensin-converting enzyme inhibition and antihypertensive properties in wheat wort.. Food chemistry, 495(Pt 3), 146533. https://doi.org/10.1016/j.foodchem.2025.146533